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Abstract
MicroPET imaging studies using
18F-nifene, a new positron emission tomography (PET) radiotracer for nicotinic
acetylcholinergic receptors (nAChR) a4b2 receptors in rats, have been carried out. Rats were imaged for 90 min
after intravenous injection of
18F-nifene (0.8 to 1 mCi), and binding potential (BPND) was measured.
18F-Nifene
binding to thalamic and extrathalamic brain regions was consistent with the a4b2 nAChR distribution in the rat
brain. Using the cerebellum as a reference, the values for the thalamus varied less than 5% (BPND = 1.30, n = 3),
confirming reproducibility of
18F-nifene binding.
18F-Nifene microPET imaging was also used to evaluate effects of
nicotine in a group of Sprague-Dawley rats under isoflurane anesthesia. Nicotine challenge postadministration of
18F-nifene demonstrated reversibility of
18F-nifene binding in vivo. For a4b2 nAChR receptor occupancy
(nAChROCC), various doses of nicotine (0, 0.02, 0.1, 0.25, and 0.50 mg/kg nicotine free base) 15 min prior to
18F-
nifene were administered. Low-dose nicotine (0.02 mg) reached > 80% nAChROCC while at higher doses (0.25 mg)
> 90% nAChROCC was measured. The small amount of
18F-nifene binding with reference to the cerebellum affects
an accurate evaluation of nAChROCC. Efforts are underway to identify alternate reference regions for
18F-nifene
microPET studies in rodents.
Background
Nicotinic a4b2 receptors play an important role in
many CNS disorders such as Alzheimer’sd i s e a s e ,P a r -
kinson’s disease, Schizophrenia, mood disorders, and
nicotine dependence. Much work is being done on
radiotracer compounds with high binding affinity as well
as faster kinetics which can be used as an aid to visua-
lize the nicotinic receptors and their involvement in
neurological disorders [1]. Both 5-
123I-iodo-A-85380 and
2-
18F-fluoro-A-85380 have a high affinity for the a4b2
receptors with scan times exceeding several hours. In
order to reduce the scan time, emphasis was placed on
developing a tracer with faster kinetics. We have devel-
oped
18F-nifene (2-
18F-fluoro-3-[2-((S)-3-pyrrolinyl)
methoxy]pyridine; Figure 1), a nicotinic a4b2 receptor
agonist which is suitable for positron emission tomogra-
phy (PET) imaging (Ki = 0.50 nM; [2,3]). Imaging times
in nonhuman primates with
18F-nifene [2] were reduced
significantly compared to
18F-flouroA-85380 [4].
Nicotine has a high affinity for a4b2 nicotinic acetyl-
cholinergic receptors (nAChR) receptors (Ki =1 . 6 8n M ,
[3]). Cigarette smoking and nicotine (a major compo-
nent of tobacco) have been shown to have a direct and
significant occupancy of a4b2 nAChR receptors [5-7].
Studies have also shown an increase in a4b2 receptor
density binding sites in rat and mice brains upon expo-
sure to nicotine [8-10]. Chronic tobacco smoking
increases the number of high affinity nAChRs in various
brain areas [11]. Human postmortem data have shown
the presence of a4b2 nAChR receptors in the subicu-
lum, which are upregulated in smokers [10]. Human
imaging studies, using SPECT imaging agent 5-
123I-
iodo-A-85380 and PET imaging agent 2-
18F-fluoro-A-
85380, have also identified an increase in receptor den-
sity among smokers versus nonsmokers, suggesting 2-
18F-fluoro-A-85380 to be a reliable PET method for
further tobacco studies [12,13]. As reported recently,
nicotine from typical cigarette smoking by daily smokers
is likely to occupy a majority of a4b2 receptors and
lend them to a desensitized state [5]. Thus, noninvasive
imaging is playing a major role in understanding nico-
tine dependency [14,15].
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provided the original work is properly cited.The focus in this work is on in vivo evaluation of
18F-
nifene binding to a4b2 nicotinic receptors in rodent
brain regions using microPET. In an effort to establish
18F-nifene microPET studies in the rat model, our objec-
tives were the following: (1) evaluate in vivo
18F-nifene
in the normal rat model using microPET and confirm
by ex vivo microPET and autoradiography, (2) carry out
test-retest microPET studies in the rat model in order
to evaluate reproducibility of
18F-nifene microPET bind-
ing, and (3) measure changes in
18F-nifene binding in
the rat model using microPET at different doses of nico-
tine. These findings will assist in our eventual goal to
evaluate the role of a4b2 nAChR in nicotine depen-
dency using the rodent model.
Methods
General methods
All chemicals and solvents were purchased from Aldrich
Chemical (Aldrich Chemical Company, Wilwaukee, WI,
USA) and Fisher Scientific (Fisher Scientific UK Ltd., Lei-
cestershire, UK). Deionized water was acquired from
Millipore Milli-Q Water Purification System (Millipore,
Billerica, MA, USA). Gilson high-performance liquid
chromatography (HPLC) was used for the semiprepara-
tive reverse phase column chromatography. Fluorine-18
fluoride was produced via MC-17 cyclotron using oxy-
gen-18-enriched water. Radioactivity was counted using a
Capintec dose calibrator while low level counting was
done using a well counter. Inveon preclinical Dedicated
PET (Siemen’s Inc., Munich, Germany) was used for the
microPET studies which has a resolution of 1.45 mm
[16]. Both in vivo and ex vivo images of the rat brains
were obtained using the Inveon microPET scanner and
were analyzed using the Acquisition Sinogram Image
Processing (ASIPRO, Siemens Medical Solutions USA,
Inc., Knoxville, TN, USA) and Pixelwise Modeling Soft-
ware (PMOD Technologies, Zurich, Switzerland). Slices
of the rat brain were prepared at 10 to 40-μm thick using
the Leica 1850 cryotome (Leica Instruments, Nussloch,
Germany). In vitro-o rex vivo-labeled brain sections were
exposed to phosphor films (Perkin Elmer Multisensitive,
Medium MS) and were read using the Cyclone Phosphor
Imaging System (Packard Instruments, Meriden, CT,
USA). An analysis of in vitro or ex vivo autoradiographs
was done using the Optiquant Acquisition and Analysis
software (Packard Instruments, Meriden, CT, USA). All
animal studies have been approved by the Institutional
Animal Health Care and Use Committee of the Univer-
sity of California, Irvine.
Radiolabeling
A synthesis of
18F-nifene was carried out following
reported procedures (Pichika et al. 2006). The auto-
mated radiosynthesis of
18F-nifene was carried out in
the chemistry processing control unit box. An Alltech
C18 column (10 μm, 250 × 10 mm
2)w a su s e df o r
reverse phase HPLC purification and specific activity of
18F-nifene was approximately 2,000 Ci/mmol.
MicroPET
18F-nifene studies
Male Sprague-Dawley rats were fasted 24 h prior to the
time of scan. On the day of the study, rats were anesthe-
tized using 4.0% isoflurane. The rat was then positioned
on the scanner bed by placing it on a warm water circu-
lating heating pad, and anesthesia was applied using a
nose cone. A transmission scan was subsequently
acquired. The preparation of the dose injection was as
follows: 0.7-1.0 mCi of
18F-nifene was drawn into a 1-
mL syringe with a 25-gauge needle and was diluted with
s t e r i l es a l i n et oaf i n a lv o l u m eo f0 . 3m L .T h ed o s ew a s
injected intravenously into the tail vein of the rat. Iso-
flurane was reduced and maintained at 2.5% following
the injection. The scans were carried out for 90 min
and were acquired by the Inveon microPET in full list
mode. The list mode data were collected dynamically
which were rebinned using a Fourier rebinning algo-
rithm. The images were reconstructed using a two-
dimensional Filter Back Projection using a Hanning Fil-
ter with a Nyquist cutoff at 0.5, and were corrected for
attenuation using the Co-57 attenuation scan data. A
calibration was conducted to Becquerel per cubic centi-
meter units using a germanium-68 phantom which was
scanned in the Inveon microPET and was reconstructed
under the same parameters as the subjects. Analyses of
all data were carried out using the Acquisition Sinogram
Image Processing IDL’s virtual machine (ASIPRO VM)
and Pixelwise Modeling software (PMOD 3.0). The test
and retest microPET studies on the same animal were
carried out within an interval of approximately 2 weeks.
Metabolite analysis
Blood was collected at four different time points (5, 15,
60, and 90 min) after the injection of
18F-nifene. The
blood was centrifuged for 5 min at 3,000 g. The plasma
was separated and counted. Acetonitrile was added to
the blood samples, and the organic layer was spotted on
the analytical thin layer chromatography (TLC) plates
N
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Figure 1 Chemical structure of
18F-nifene.
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and was developed in 15% methanol in dichloro-
methane. A sample of the plasma was also collected
prior to the injection of
18F-nifene and was spiked with
the tracer and was used as a standard.
Male Sprague-Dawley rats were injected intravenously
(IV) with 0.5 mCi of
18F-nifene in a total volume of 0.3
mL and were sacrificed 40 min after injection. The
brain was extracted and dissected into two hemispheres.
The sagittal sections of 40-μm thickness were obtained
from the left hemisphere using the Leica 1850 cryotome
and were exposed to phosphor films overnight. The
films were read using the Cyclone Phosphor Imaging
System and were analyzed using the Optiquant software.
The right hemisphere was homogenized with 1.15% KCl
(2 mL), and this homogenized mixture was vortexed
with 2% acetic acid in methanol (2 mL). This mixture
was centrifuged for 10 min at 10,000 g, and the super-
natant was removed for analysis. RadioTLC (9:1,
dichloromethane and methanol) was obtained for both
18F-nifene standard and the brain extract.
Ex vivo microPET
In order to ascertain the brain uptake of
18F-nifene, after
completion of the in vivo microPET scans, the rats were
sacrificed and the brain was extracted for ex vivo micro-
PET imaging. The whole brain was placed in a hexago-
nal polystyrene weighing boat (top edge side length, 4.5
cm; bottom edge side length, 3 cm) and was covered
with powdered dry ice. This boat was placed securely on
the scanner bed, and a transmission scan was acquired.
Subsequently, a 60-min emission scan was acquired by
the Inveon microPET scanner in full list mode. The list
mode was collected in a single frame, and a reconstruc-
tion of the images was similar to the procedure
described previously in the section “MicroPET
18F-
nifene studies.” T h ei m a g e sw e r ea n a l y z e du s i n gt h e
ASIPRO VM and PMOD 3.0 software.
Ex vivo autoradiography
The brain after the ex vivo microPET acquisition in the
section “Ex vivo microPET” was removed from the dry
ice and was rapidly prepared for sectioning. Horizontal
sections (40-μmt h i c k )c o n t a i n i n gb r a i nr e g i o n so ft h e
thalamus, subiculum, cortex, striatum, hippocampus, and
cerebellum were cut using the Leica CM1850 cryotome.
The sections were air-dried and exposed to phosphor
films overnight. The films were read using the Cyclone
Phosphor Imaging System. The regions of interest of the
same size were drawn and analyzed on the brain regions
rich in a4b2 nicotinic receptors using the OptiQuant
software, and the binding of
18F-nifene was measured in
digital light units per square millimeter.
MicroPET studies of nicotine challenge
Nicotine challenge experiments were of two types. In
order to demonstrate reversibility of bound
18F-nifene
and to measure the off-rate, the postinjection nicotine
effects were first measured. Sprague-Dawley rats were
injected with
18F-nifene (0.2 to 0.5 mCi, IV) and at
approximately 30 min postinjection of the
18F-nifene,
0.3 mg/kg of nicotine free base (administered as a ditar-
tarate salt from Sigma Chemical Company, St. Louis,
MO, USA) was administered intravenously. The total
time of scan was 90 min and was acquired in full list
mode, similar to the protocol for the control scans
described in “MicroPET
18F-nifene studies.” Before and
after images were analyzed using the PMOD 3.0 soft-
ware, and a time-activity curve was generated.
The second set of nicotine challenge experiments were
designed to measure a4b2 nAChR receptor occupancy
(nAChROCC) by nicotine. Male Sprague-Dawley rats
were preinjected intravenously with nicotine using saline
for baseline, and four different doses of nicotine (0.02,
0.1, 0.25, and 0.5 mg/kg free base, administered as a
ditartarate salt) were diluted in a total volume of 0.3 mL
sterile saline. Nicotine was injected 15 min prior to
intravenous injection of
18F-nifene (0.8-1.0 mCi). Once
anesthetized, the rats were scanned for 90 min using the
Inveon microPET scanner in full list mode. Dynamic
data were reconstructed and analyzed as described in
the section “MicroPET
18F-nifene studies.” Time-activity
curves were measured and analyzed using the ASIPRO
VM and PMOD 3.0 software. Percent occupancy was
calculated from: (Thalcont -T h a l nic/Thalcont]) × 100,
where Thalcont is the percent injected dose of
18F-nifene
in the brain regions of the control study, and Thalnic is
the percent injected dose of
18F-nifene in the brain
regions of the nicotine study at 60 min postinjection of
18F-nifene.
Results
MicroPET
18F-nifene binding studies
Ar a p i du p t a k eo f
18F-nifene was observed in the brain
with levels of approximately 1% of injected dose per
cubic centimeter. Thalamic regions exhibited the highest
retention as it has a maximum amount of a4b2 recep-
tors. Significant levels of uptake were observed in the
various regions of the cortex while very little binding is
present in the cerebellum (Figure 2A,B,C). Time-activity
curves of the thalamus, frontal cortex, and cerebellum
in Figure 2D show initial rapid uptake in various brain
regions followed by greater retention in the thalamus
and cortex compared to the cerebellum. A ratio of the
uptake for the thalamus and frontal cortex against the
reference region cerebellum reached a plateau at
approximately 60 min postinjection. The thalamus to
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to cerebellum ratio was 2.3.
Metabolite analysis
Following the injection of
18F-nifene, blood was col-
lected at different time points to measure metabolites in
the blood plasma. Figure 3A shows a decrease in the
amount of parent as well as metabolites found in the
blood plasma during the 90 min.
18F-Nifene standard
was used to compare the tracer found in the blood
plasma. Figure 3B represents about 42% of
18F-nifene
remaining in the blood plasma at 90 min (compared to
that measured at 5 min pi) while the levels of metabo-
lites were significantly reduced in the blood plasma at
90 min.
Radiochromatograms were attained from running
brain extracts and were compared to the peak to the
parent compound providing evidence that the primary
species within the brain of the rat was
18F-nifene. After
sacrificing the rat, the brain was excised and dissected
into the left and right hemispheres. Figure 3C,D shows
the sagittal brain slices of the left hemisphere represent-
ing the total binding of
18F-nifene revealing maximal
binding in the thalamus followed by extrathalamic
regions such as the cortex and subiculum. The cerebel-
lum had the least amount of activity. A thin layer chro-
matographic analysis of the extract of the homogenized
right hemisphere shown in Figure 3F closely correlates
with the retention of
18F-nifene standard (Figure 3D).
No other significant metabolite peak was observed in
the brain extract.
Test-retest
Test and retest studies were investigated in a group of
rats (Figure 2). Binding of
18F-nifene in each region of
the brain remained consistent among the studies. Figure
2 represents the time-activity curves for a test-retest
study in one animal. The curve seen for the retest study
follows the same pattern as the test study. By 60 min
into the scan, nonspecific binding is seen to be cleared
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Figure 2 In vivo microPET rat brain test-retest study. (A) Horizontal, (B) sagittal, (C) coronal of
18F-nifene. The thalamus (TH) shows the
highest binding followed by the cortex (COR) and the cerebellum (CB). Test-retest study showing consistency in binding of
18F-nifene to the
thalamus with respect to the cerebellum. BPND for the test study was 1.69 while the retest study was 1.64.
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binding potentials for the three rats were calculated and
were found to vary between 1.03 and 1.69, but within
subject, the test-retest error was approximately 3%
(Table 1).
Ex vivo studies
Ex vivo microPET imaging of the excised brain after 90
min of in vivo scans was carried out for another 60 min.
Results clearly show binding of
18F-nifene in the thala-
mus, cortical regions with little binding in the cerebel-
lum (Figure 4A,B,C). This is consistent with the in vivo
images shown in Figure 2A,B,C.
Ex vivo autoradiographs revealed a significant amount
of detail that was not readily apparent in the microPET
images. The thalamus exhibit e dt h eh i g h e s ta m o u n to f
18F-nifene binding. The subiculum had a higher amount
A B
18F-Nifene
Standard
Brain 
Hemisphere
Homogenate 
Extract
E
F
C D
TH TH
COR COR
CB CB
Figure 3 Blood and brain metabolite analysis in rats postadministration of intravenous
18F-nifene. (A) Blood plasma collected at different
time points (5, 15, 60, and 90 min) and compared to
18F-nifene standard on TLC. A polar metabolite is seen, but the predominant radioactive
species is
18F-nifene. (B) Analysis of TLC in (A) indicates 42% of
18F-nifene (blue) remaining at 90 min with little polar metabolites (red) remaining
in the plasma. (C) Ex vivo rat brain was dissected into two hemispheres–the left hemisphere was cut into 40-μm thick sagittal brain sections and
were scanned to reveal brain areas. (D) Binding of
18F-nifene in the thalamus (TH), cortex (COR), and least binding in the cerebellum (CB) was
observed. (E) RadioTLC of
18F-nifene standard with 9:1 CH2Cl2:CH3OH. (F) RadioTLC of brain extracts with 9:1 CH2Cl2:CH3OH showing the
presence of
18F-nifene.
Table 1 Test-retest
18F-nifene binding potential in
thalamus
Test Retest Mean %Error
Rat 1 1.69 1.64 1.67 3.0%
Rat 2 1.17 1.21 1.19 3.4%
Rat 3 1.06 1.03 1.05 2.9%
Error estimates are given as [(Scan1-Scan2)/(Scan1 + Scan2)/2] × 100
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able in the microPET data. The cortex had a significant
amount of binding consistent to that observed in the
microPET imaging data. The cerebellum had the lowest
amount of
18F-nifene binding in the ex vivo autoradio-
graphs. Autoradiographic ratios with respect to the cere-
bellum in the various brain regions were: thalamus =
4.60, subiculum = 2.39, cortex = 1.83, striatum = 1.46.
These ratios are in close agreement to the ratios mea-
sures by microPET ex vivo (Table 2).
MicroPET studies of nicotine challenges
In the first set of experiments with nicotine,
18F-nifene
bound in the thalamus (Figure 5A) was displaced by IV
administration of 0.3 mg/kg of nicotine (Figure 5B). The
time-activity curve for this competition of nicotine with
18F-nifene in the thalamus is shown in Figure 5C which
shows the displacement of most of the
18F-nifene from
the thalamus. Nicotine had little effect in the cerebel-
lum. The nicotine-induced in vivo off-rate measured for
18F-nifene was 0.06 min
-1 (Figure 5D).
Occupancy of a4b2n A C h R OCC by nicotine was mea-
sured by dose escalation competition experiments of
nicotine with
18F-nifene. A change in thalamus binding
at baseline was measured at different nicotine doses of
injected nicotine. The displacement of
18F-nifene was
found with the pre-nicotine challenges. With each dose
increase of nicotine, a steady increase in binding occu-
pancy was found. The results are summarized in
Table 3. Eighty percent binding occupancy was seen
with just 0.02 mg/kg of nicotine while 94% binding
occupancy was found with 0.5 mg/kg. Figure 6 presents
a steady decrease of
18F-nifene with the competition of
nicotine at different doses.
Discussion
Our primary goal was to evaluate
18F-nifene binding to
the a4b2 receptors in thalamic and extrathalamic brain
regions of rodents using microPET imaging.
18F-Nifene,
an agonist, was developed with fast binding kinetics and
a shorter scan time in order to image the a4b2 nicotinic
receptors. This is useful in the assessment of nicotinic
receptors in neurological diseases. MicroPET studies in
rats validated the faster binding profile of
18F-nifene
thus providing shorter scan times. Maximum binding
was found in the thalamus, while moderate binding is
seen in the cortex, and minimal binding in the cerebel-
lum. Time-activity curves for the thalamus, cortex, and
cerebellum show that
18F-nifene peaks early into the
scan, and nonspecific binding in the cerebellum cleared
rapidly. Thalamus to cerebellum ratios were > 3.0 and
cortex to cerebellum were approximately 2. Thus,
18F-
nifene allows shorter duration PET studies for quantita-
tive measures of a4b2 receptors compared to 2-
18F-FA-
85380 which has been shown to require 5 h to reach
steady state in rodents [17].
No lipophilic metabolites of
18F-nifene were detected
in plasma extracts, and a significant amount of
18F-
nifene parent remained in the blood after 90 min of the
PET study. The absence of lipophilic metabolites was
also confirmed using brain extracts of rats injected with
18F-nifene. Only
18F-nifene was detected in the brain
extracts.
The binding of
18F-nifene to a4b2 receptors of the
rodent brain in microPET studies gave results consistent
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CB
TH
COR E D
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TH
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C
Figure 4 Ex vivo microPET and autoradiographic brain images
of a rat. MicroPET images ((A) horizontal, (B) coronal, and (C)
sagittal) validate maximum binding in the thalamus (TH) followed
by the cortical regions (COR). An autoradiograph of the brain in (A)
showing 10-μm horizontal sections (D) and an anatomical view (E)
of the slice in (D).
18F-nifene binding followed the order TH >
subiculum (SUB) > cortex (COR) > striatum (STR) > cerebellum (CE).
Table 2 Measured
18F-nifene ratios of rat brain regions
with reference to the cerebellum
Brain
regions
In vivo
microPET
a
Ex vivo
microPET
b
Ex vivo
autoradiographs
c
Thalamus 3.13 ± 0.29 3.92 ± 0.49 4.60 ± 0.52
Subiculum - 2.28 ± 0.24 2.39 ± 0.15
Cortex 1.98 ± 0.10 2.05 ± 0.17 1.83 ± 0.19
Striatum 1.52 ± 0.39 1.77 ± 0.28 1.46 ± 0.07
Average of four animals with standard deviations;
aRatio measured at 85-90
min postinjection of
18F-nifene;
bRatio measured in the 60-min summed ex
vivo scan of the same rats;
cRatios measured in sections after the ex vivo scans
of the same rats.
Kant et al. EJNMMI Research 2011, 1:6
http://www.ejnmmires.com/content/1/1/6
Page 6 of 9with the receptor distribution and was comparable with
the autoradiographic slices done in vitro [3]. Test-retest
results of binding potentials, summarized in Table 1,
remained consistent between scans thus confirming
reproducibility of
18F-nifene with <5% standard devia-
tion, suggesting
18F-nifene to be suitable for PET
studies. Ex vivo images, both microPET and autoradio-
graphic, confirmed binding of
18F-nifene to thalamic
and extrathalamic regions seen in the in vivo microPET
study.
Nicotine, because of its high affinity to a4b2 recep-
tors, exhibited competition with
18F-nifene. Previous in
vitro studies using 10 nM of nicotine displaced 60-65%
in the thalamus region and 300 μM of nicotine, 95%
elimination is seen in the thalamus [2]. As expected, dis-
placement of
18F-nifene binding was seen in the post-
nicotine challenge similar to that reported for 2-[
18F]F-
A-85380 [17]. Figure 6 clearly shows a drop in binding
at the time of nicotine injection (30 min into the scan),
displacing at least > 80% of
18F-nifene binding. The abil-
ity for nicotine to compete with
18F-nifene can be used
to detect changes in receptor occupancy suggesting PET
to be a valuable tool in assessing tobacco-related depen-
dence [13]. Pre-nicotine challenges at different dose
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Figure 5 In vivo displacement of
18F-nifene by nicotine. In vivo rat microPET brain slices of
18F-nifene before (A) and after (B) nicotine
challenge. (C) Time-activity curve of
18F-nifene specific binding (thalamus-cerebellum) with nicotine (0.3 mg/kg) administered at 30 min pi,
displacing
18F-nifene binding in the thalamus (inset shows dissociation rate, koff of
18F-nifene was 0.06 min
-1).
Table 3 Nicotine dose effects on
18F-nifene binding
Nicotine, mg/kg % Injected dose/cc
thalamus
Nicotine
occupancy
0 0.489 0%
0.02 0.092 81%
0.10 0.037 92%
0.25 0.031 94%
0.50 0.005 99%
Average of two measurements for each dose; receptor occupancy was
calculated on the basis of percent injected dose per cubic centimeter of
18F-
nifene in the thalamus (Thalcont - Thalnic/Thalcont × 100).
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18F-nifene occupancy with respect to nicotine. At low
doses of nicotine, 0.02 mg/kg, > 40% of receptors were
occupied while at high doses (0.5 mg/kg) > 80% recep-
tors were occupied with nicotine (Table 3). While the
cerebellum was used as a reference region, some issues
have risen questioning the validity of the cerebellum as
a reference region. With the presence of nicotinic recep-
tors in the rat cerebellum [17-19], measurement of bind-
ing potential can be complex. Studies using 2-[
18F]F-A-
85380 in rodents have reported nicotine displaceable
component in the cerebellum [17], suggesting a need for
arterial input function for accurate quantification.
Aside from the cerebellum, efforts have been under-
way to identify other regions of the brain, such as the
corpus callosum and pons as reference regions [20].
Efforts are underway in our rodent
18F-nifene studies to
identify other reference regions in the brain, other than
the cerebellum. Future work in the rodent model will
incorporate arterial blood sampling for more accurate
quantification.
Conclusions
18F-nifene binds to the a4b2 receptors in thalamic and
extrathalamic regions in rat microPET studies. With its
faster binding kinetics, short scan time, and reversible
binding,
18F-nifene is an agonist radiotracer with potential
for studying this receptor system in various rodent models.
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